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Abstract:  The aggregation of the amyloid-β-peptide (AβP) into well-ordered fibrils has 
been  considered  as  the  key  pathological  marker  of  Alzheimer‘s  disease.  Molecular 
attributes related to the specific binding interactions, covalently and non-covalently, of a 
library  of  compounds  targeting  of  conformational  scaffolds  were  computed  employing 
static lattice atomistic simulations and array constructions. A combinatorial approach using 
isobolographic analysis was stochastically modeled employing Artificial Neural Networks 
and  a  Design  of  Experiments  approach,  namely  an  orthogonal  Face-Centered  Central 
Composite Design for  small molecules, such as  curcumin and glycosylated nornicotine 
exhibiting  concentration-dependent  behavior  on  modulating  AβP  aggregation  and 
oligomerization. This work provides a mathematical and in silico approach that constitutes 
a  new  frontier  in  providing  neuroscientists  with  a  template  for  in  vitro  and  in  vivo 
experimentation. In future this could potentially allow neuroscientists to adopt this in silico 
approach for the development of novel therapeutic interventions in the neuroprotection and 
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neurotherapy of Alzheimer‘s disease. In addition, the neuroprotective entities identified in 
this study may also be valuable in this regard. 
Keywords: amyloid-β protein; Alzheimer‘s disease; molecular mechanics; artificial neural 
networks; curcumin; nicotine; isobolographic analysis; docking; central composite design; 
constraint optimization; ligand-protein complexes; synergism 
 
1. Introduction 
“Neuroscientists  are  pretty  sure  they  know  what  causes  Alzheimer’s  disease,  but  their 
theory has not yet given rise to effective drugs.”—Alison Abbott, The Plaque Plan [1] 
Neurodegenerative disorders (NDs) are sporadic and/or familial and characterized by the persistent and 
progressive loss of neuronal subtypes [2] and includes mainly Alzheimer's disease (degeneration of basal 
forebrain cholinergic neurons), Parkinson's disease (degeneration of nigro-striatal dopaminergic neurons) 
and Huntington‘s disease (striatal, hypothalamic and cortical degeneration) [2,3], stroke (necrotic infarcts 
coupled with  inflammatory gliosis),  Amyotrophic Lateral Sclerosis (ALS) (upper and lower motor 
neuronal  degeneration  and  atrophy),  multiple  sclerosis  (lesions  and  plaques)  and  
HIV-1-associated neurocognitive disorders [2,4]. NDs may impact various brain functions, such as 
movement (as in Parkinson‘s disease and ALS) or memory and cognition (as in Alzheimer‘s disease). 
Neuro-regenerative therapies include neuroprotection, nuritogenation and neurorestoration of neuronal 
subtypes especially with traumatic brain and spinal cord injuries. 
Alzheimer‘s  disease  (AD)  is  a  progressive  neurodegenerative  disorder,  encompassing  the 
deterioration  of  cognitive  functions  and  behavioral  changes,  characterized  by  the  aggregation  of 
amyloid β-protein (Aβ) into fibrillar amyloid plaques in selected areas of the brain with the lipid-carrier 
protein apolipoprotein E (apoE), the microtubule associated protein tau, and the presynaptic protein α-
synuclein [2,5–7]. High levels of fibrillary Aβ, the main constituent of senile plaques, are deposited in 
the AD brain that results in the loss of synapses, neurons and impairment of neuronal function [8]. Aβ 
is derived from the amyloid precursor protein through sequential protein cleavage by aspartyl protease, 
β-secretase and presenilin-dependent β-secretase triggering a cascade of events such as neurotoxicity, 
oxidative  damage,  and  inflammation  that  contributes  to  the  progression  of  AD.  Aβ  fibrillization 
involves formation of dimers and small oligomers followed by growth into protofibrils and fibrils via a 
complex multistep-nucleated polymerization that eventually forms Aβ plaques or deposits (Figure 1) 
[9]. 
Apart from Aβ fibrils, smaller species of aggregated Aβ, known as Aβ oligomers, also represent the 
primary toxic species in AD [10]. Anti-amyloidogenic therapy primarily involves the reduction of Aβ 
production, inhibiting secretase, increasing Aβ clearance, or blocking Aβ aggregation (with antibodies, 
peptides,  or  small  organic  molecules  that  selectively  bind  and  inhibit  Aβ  aggregate  and  fibril 
formation) via inhibition of the nucleation-dependent polymerization model [9,11]. Therefore, the use 
of small molecules and peptides that can induce the Aβ peptide to fold into an α-helical or random, 
extended chain structure and the detrimental β-sheet structures to form insoluble amyloids may offer a Int. J. Mol. Sci. 2011, 12                       
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promising alternative to the pharmacotherapy for AD as inhibitors of Aβ oligomerization [12]. Apart 
from the dose-dependent inhibition of the formation of Aβ fibrils from Aβ40 and Aβ42 and their 
extensions, destabilization of preformed Aβ fibrils is also an interesting therapeutic intervention [13]. 
A number of small molecules have been reported to inhibit Aβ fibrillogenesis or to modulate Aβ 
fibrillization thereby inhibiting Aβ-mediated cellular toxicity resulting from soluble amyloid oligomers 
or prefibrillar aggregation intermediates [14,15]. 
Figure 1. Hierarchical self-assembly of amyloid β-protein (a) amyloid-β protein oligomer; 
(b) proto-fibril; (c) fibril; and (d) plaque deposit. 
 
Drug discovery, modeling and delivery techniques have benefitted profoundly by the adoption of 
computational methods that assist in the design of new therapeutic strategies in a more rapid and 
intricate  manner.  In  silico  drug  modeling  that  was  employed  in  the  present  study,  encompasses 
computational  methodologies  for  compound  database searching that utilize  data from  static lattice 
atomistic simulations of protein-ligand interactions to design a rationalized combinatorial approach for 
the neuroprotection and neurotherapy of AD based on the molecular interactions of small therapeutic 
entities with the Aβ-42 monomer. The various steps constituting the current in silico modeling process 
involved: (i) identifying effective neuroprotective entities (NEs) of therapeutic interest based on energy 
minimizations of the protein-NEs complexes (using Molecular Mechanics Simulations and selection of 
the most sensitive NEs employing Artificial Neural Networks optimization); (ii) recognizing the site of 
interaction of the selected NEs on the amyloid protein (using Molecular Mechanics Force Fields and 
Advanced Docking Techniques); (iii) employing Interactive Data Analysis as a combinatorial approach 
(using Isobolographic Analysis); and (iv) determining the design of the synergistic combinations and Int. J. Mol. Sci. 2011, 12                       
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their optimization (via Design of Experiments using a Face-Centered Central Composite Design) to 
obtain  the  most  stabilized  geometrical  preferences  of  the  protein-NEs  complexes  derived  from 
Molecular Mechanics calculations. Ligand- and target structure-based strategies are widely used in 
virtual screening, but there is currently no methodology available that integrates the extent of the above 
modeling approaches. In this study, we provide an in silico approach that has combined molecular 
mechanics, stochastic sensitivity analysis, Design of Experiments and interaction studies to design a 
combinatorial therapeutic strategy for the neuroprotection and neurotherapy of AD. 
2. Results and Discussion 
Aβ,  similar  to  other  globular  proteins,  appear  to  require  essential  contribution  from  both 
hydrophobic and ionic interactions during structure formation with hydrophobicity providing a large 
energetic  contribution  [16,17].  Apart  from  providing  the  stabilization  energy,  these  non-bonding 
interactions provide loose network structures, so that Aβ can tolerate residue replacements at packing 
positions without losing its stability or shape. Considering these generalized rules of protein structure, 
it has been assumed that binding of small molecules to a site on Aβ with significant specificity may 
inhibit amyloid fibril formation  and other types of aggregation [18]. Therefore, the mechanism of 
action  of  amyloid  aggregation  inhibitors  in  terms  of  blocking  oligomer  formation,  blocking  fibril 
formation,  de-aggregating  the  preformed  fibers  or  rendering  Aβ  insoluble  holds  promise  for 
neuroprotection as well as neurotherapy. The chemical disruption of this β-sheet containing polymers 
was exemplified approximately two decades ago, when the conformational modification of the KLVFF 
region of Aβ was postulated as a lead for the development of anti-Aβ agents [19]. The following small 
molecular  candidates  reported  previously  to  bind  amyloid,  to  modulate  protein aggregation and/or 
toxicity or screened for such activities were modeled in this study for their ability to interact with the 
Aβ-42 oligomer and included the following: apigenin (APG) [20], congo red (CR) [21,22], curcumin 
(C) [9,13], dihydroxybenzophenone (DHB) [20], indomethacin (IND) [23], thioflavin T (ThT) [24], 
hexamethylpyridinium (HMP) [18], glycosylated nornicotine (G) [12], neocuproine (NEO) [25] and 
polystyrene sulfonate (PSS) [26]. 
2.1. Static Lattice Atomistic Simulations of Protein-NE Complexes to Select Optimal Neuroprotective 
Entities for Effective Aβ Protein Binding via AMBER Force Field 
In  order  to  select  the  best  Neuroprotective  Entity  (NE)  for  potential  neuroprotective  or 
neurotherapeutic activity against Alzheimer‘s disease (AD) or influencing the fibrillization or plaque 
formation  of  Aβ-protein,  Molecular  Mechanics  was  employed  to  determine  the  individual  
protein-ligand interaction energies between Aβ1-42 and 10 NEs in order to understand the structures 
(Figure 2) and energetics (Table 1) of protein-NE complexes resulting from the interplay between the 
bonding  and  non-bonding  potentials.  This  provided  the  comparative  in  silico  profile  of  the  most 
sensitive  NEs  of  Aβ  without  undertaking  any  extensive  in  vitro  and  in  vivo  studies.  Molecular 
Mechanics described the energies of the complexes in terms of a simple function potentials typically 
consisting of two sets of terms: one accounted for distortion from ideal bond distances and angles and 
the other for non-bonded Van der Waals (VdW) and Coulombic interactions, where the bond and angle 
terms  were  defined  in  a  self-consistent  manner  giving  an  energy  minimum  at  an  unstrained  Int. J. Mol. Sci. 2011, 12                       
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structure [27]. The individual energies of the NE molecules were insignificant (as compared to that of 
the target Aβ) to be considered for the computation of ΔEinteraction (EHost:Guest − EHost − EGuest). The total 
steric energy, considered for the interpretation of modeling characteristics, are listed in Table 1. Most 
of the NEs studied demonstrated high energy stabilized structures (Table 1) and interactions with Aβ in 
terms of H-bonding (Figure 2). 
Table 1. Computed energy parameters (kcal/mol) of the protein-NE complexes. 
Molecule  Total 
Energy
a 
Bond 
Length
b 
Bond 
Angle
c 
Dihedral
d  VdW
e  H-bond
f  ES
g 
AβP  −642.58  8.86  112.07  54.04  −80.42  −11.19  −728.89 
AβP-CR  −596.30  10.97  174.75  74.36  −103.44  −18.33  −734.44 
AβP-PSS  −606.71  9.51  171.42  65.70  −102.03  −18.17  −733.17 
AβP-NEO  −618.54  8.28  107.03  51.66  −83.07  −16.86  −686.59 
AβP-HMP  −619.63  8.34  103.03  50.15  −89.66  −12.64  −677.26 
AβP-APG  −636.01  8.34  108.51  49.90  −89.94  −17.39  −692.48 
AβP-ThT  −638.33  10.51  135.38  67.69  −108.33  −16.17  −727.29 
AβP-IND  −643.98  9.51  128.76  65.28  −99.51  −17.97  −730.10 
AβP-C  −652.31  9.63  121.25  68.97  −102.44  −18.38  −731.38 
AβP-DHB  −653.94  9.42  114.75  64.71  −94.19  −18.50  −730.18 
AβP-G  −666.07  9.15  119.25  61.92  −104.52  −18.62  −733.21 
a Total steric energy for an optimized structure 
b Bond stretching contributions, reference values were assigned to all of a structure's bond lengths 
c Bond angle contributions, reference values were assigned to all of a structure's bond angles 
d Torsional contribution arising from deviations from optimum dihedral angles 
e van der Waals interactions due to non-bonded interatomic distances 
f Hydrogen-bond energy function 
g Electrostatic energy 
The molecules are listed in decreasing order of the total minimized energy obtained after MM+ 
simulations. It is evident from the results that Congo Red and Glyconornicotine constituted the least 
and most stable geometrical configurations after molecular interaction with Aβ protein (a difference of 
≈70 kcal/mol).  However,  the  VdW  and  the  electrostatic  energies  in  this  case  (Congo  Red  and 
Glyconornicotine) differed only by 1.08 and 1.23 kcal/mol, respectively. Here, the torsional energy 
(bond  angle)  was  the  determining  factor  in  the  energy  minimization.  Similarly,  in  the  case  of 
Neocuproine, HMP, Apigenin, Thioflavin T, Curcumin and DHB, the energy differences were too 
close to determine their sensitivity and hence effectiveness against Aβ. Furthermore, even if only those 
NEs were considered which provided more stabilized structures than Aβ, 4 NEs will remain with 
Indomethacin  very  close  to  Aβ.  Indomethacin,  Curcumin,  DHB  and  Glyconornicotine  are  less 
stabilized than Aβ in terms of Bond Length (bond energy) and torsional energy (angle). It is therefore 
extremely convoluted to isolate the most sensitive NEs and the most significant energy values for the 
inhibition of Aβ protein fibrillization or insolubilization of the plaque. To manage these issues machine 
learning approaches, such as Artificial Neural Networks (ANN) was employed for the selection of NEs 
with the most efficient/sensitive binding to Aβ protein. Int. J. Mol. Sci. 2011, 12                       
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Figure 2. Energy minimized geometrical preferences of the protein-NE complexes derived 
from  Molecular  Mechanics  computations:  (a)  apigenin;  (b)  congo  red;  (c)  curcumin;  
(d) dihydroxybenzophenone; (e) glycosylated nornicotine; (f) hexadecylmethylpiperidinium; 
(g) indomethacin; (h) neocuproine; (i) polystyrene sulfonate and (j) thioflavin T. 
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2.2. Selection of Neuroprotective Entity (NE) Using Artificial Neural Networks 
A maximum of 10,000 epochs were run on NeuroSolutions
® V5 (NeuroDimension Inc., Gainsville, 
FL, USA) for ensuring optimal training of data. Sensitivity analysis was used for extracting the cause 
and effect relationship between the inputs and the outputs of the network. This provided feedback 
pertaining to the input variable that was the most significant by testing the network with regard to its 
sensitivity  about  the  binding  to  Aβ,  thus  elucidating  the  NEs  that  were  most  significant.  Table 2 
represents the input data in the form of energy attributes (obtained from the Molecular Mechanics 
simulations using AMBER Force Field) that was trained and the parameters used to construct the 
neural network are as shown in Table 3. 
Table 2. Input Data for neural network training, computations and sensitivity testing. 
Attribute  CR
a  HMP
b  ThT
c  C
d  G
e  APG
f  DHB
g  IND
h  NEO
i  PSS
j  AβP
k 
Total Energy  −596.30  −619.63  −638.33  −652.31  −666.07  −636.01  −653.94  −643.98  −618.54  −606.71  −642.58 
Bond Length  10.79  8.37  10.35  9.64  9.13  8.39  9.48  9.55  8.29  9.53  8.81 
Bond Angle  174.75  103.03  135.38  121.25  119.25  108.51  114.75  128.76  107.03  171.42  112.07 
Dihedral  74.36  50.15  67.69  68.97  61.920  49.90  64.71  65.28  51.66  65.70  54.04 
VdW  −103.44  −89.66  −108.30  −102.42  −104.55  −89.94  −94.19  −99.51  −83.07  −102.03  −80.42 
H-bond  −18.33  −12.64  −16.17  −18.38  −18.627  −17.39  −18.50  −17.97  −16.86  −18.17  −11.19 
ES  −734.44  −677.26  −727.29  −731.38  −733.21  −692.48  −730.18  −730.10  −686.59  −733.17  −728.89 
a  Congo  red; 
b  Hexadecylmethylpiperidinium; 
c  Thioflavin  T;
  d  Curcumin; 
e  Glycosylated  nornicotine; 
f  Apigenin;
  
g Dihydroxybenzophenone; 
h Indomethacin; 
I Neocuproine; 
j Polystyrene sulfonate; 
k Amyloid-β Protein. 
Table 3. Artificial Neural Networks construction parameters employing a neural builder. 
Parameter  Setting 
Hidden layer  1 
Exemplars  17 
Output Processing element  1 
Transfer function  SigmoidAxon:sigmoid (0/1) 
Learning rule  ConjugateGradient: second order method 
for gradient 
Maximum Epochs   10,000: Supervised Learning Control 
Termination at Mean Square Error; Load Best Weights Approach 
Probe Configuration  Quantitative-MatrixViewer, MatrixEditor;  
Qualitative-MegaScope, Hinton 
For the 10 NEs employed in this study, the MLP network was able to accurately confirm that 
Curcumin and Glyconornicotine were the most significant NEs in terms of energy attributes of protein-
ligand complexes based on the empirical data. The approach followed in this work required prior 
assumption for the selection of a mathematical model before applying the ANN models so as to be able 
to  confirm  the  sensitivity  coefficients  of  the  various  NEs  as  input  variables  that  significantly 
contributed to characterizing the energy values. In order to obtain accuracy and maximum degree of 
precision, the training was undertaken twice (i.e., primary and secondary training). The primary run 
(out of three runs) provided the lowest Mean Square Error (MSE) value. The leveling of the MSE with Int. J. Mol. Sci. 2011, 12                       
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standard deviation (SD) boundaries for the training runs indicated highly improved data modeling as 
illustrated in Figure 3. Table 4 depicts the average of the MSE values for the three runs of the training, 
the best network run out of 10,000 epochs, and the overall efficiency and performance of the neural 
network during the data training.  
Figure 3. Average MSE for the ANN trains with standard deviations for 10,000 epochs. 
 
Table 4. Neural network indicators characterizing the efficiency and performance of data in 
the training as per ANN. 
Best Network  Training  Performance  AβP 
Epoch #  10,000  MSE  3.457756864 
Minimum MSE
a  7.93561E-06  NMSE
b  3.31882E-05 
Final MSE  7.93561E-06  MAE
c  1.749398046 
-  -  Min Abs Error
d  0.887866082 
-  -  Max Abs Error
e  2.866526507 
R
2  -  -  0.999983413 
aMSE: Mean square error 
bNMSE: Normalized mean square error 
cMAE: Mean absolute error 
dMin Abs Error: Minimum absolute error 
eMax Abs Error: Maximum absolute error 
Basing  on  the  results  obtained,  it  was  evident  that  the  training  model  was  highly  efficient  
(MSE = 7.93561E-06). Results revealed a highly satisfactory fit for the input variables (R
2 = 0.999). 
The performance criterion employed to assess the closeness and correlation between the desired and 
the actual network output for energy attributes of Aβ protein evidenced an extremely close mapping 
between the two outputs as illustrated in Figure 4.  Int. J. Mol. Sci. 2011, 12                       
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Figure 4. Mapping of correlation between desired and actual network output. 
 
The sensitivity coefficient of each NE against the energy attributes of AβP is as shown in Figure 5. 
Glyconornicotine presented with the highest sensitivity against the energy attributes of AβP closely 
followed by Curcumin. This revealed their high capacity in stabilizing their respective protein-NE 
complexes. This behavior may be attributed to their high degree of non-bonding interaction in terms of 
Van der Waals forces, electrostatic interactions and H-bonding as shown in Table 1 and Figure 2. The 
sequence of the other remaining NEs in terms of sensitivity against AβP was NEO > PSS > APG > CR 
> HMP > IND > DHB >> ThT. The low sensitivity against AβP shown by DHB and IND despite 
forming highly stabilized protein-NE complexes (Table 1 and Figure 2) may be associated with higher 
torsional  energy  and  lower  Van  der  Waals  forces.  Results  obtained  from  ANN  sensitivity  testing 
confirmed  the  relevance  and  efficiency  of  neural  networks  in  optimization  of  ligand  selection  for 
effective Aβ protein targeting from an in silico modeling viewpoint. 
Figure 5. A typical bar chart showing the sensitivity coefficients of each NE against AβP 
following ANN sensitivity testing.  
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2.3. Binding of Selected Neuroprotective Entities (NEs) to the Amyloid β-Protein 
2.3.1. Molecular Mechanics Simulations 
Static lattice atomistic simulations of protein-NE complexes for the ANN selected NEs (Curcumin 
and  Glyconornicotine) exhibiting most sensitive Aβ protein binding was performed to explore the 
active sites for binding of the NEs. The minimizations were performed through the standard protocol 
described  earlier  in  this  paper.  The  H-bonds  were  recomputed  after  the  AMBER  Force  Field 
computations  as  depicted  in  Figure  6.  Curcumin,  a  phenolic  yellow  pigment  with  potent  
anti-inflammatory  and  antioxidant  activities,  has  been  reported  to  suppress  oxidative  damage, 
inflammation,  cognitive  deficits,  and  amyloid  accumulation  thereby  affecting  Aβ  accumulation, 
oxidative damage, and inflammation, and other risks associated with Alzheimer‘s disease (AD) [8]. 
Additionally,  the  molecular  structure  of  Curcumin  has  been  investigated  for  its  effects  on  Aβ 
aggregation whereby in vitro and in vivo studies demonstrated that Curcumin bound plaques, reduced 
amyloid levels and plaque burden, blocked aggregation and fibril formation as well as de-aggregation 
of Aβ [9]. In the present study, we modeled Curcumin molecule(s) in a close vicinity of Aβ, where it 
was found that Curcumin mostly formed H-bonds with the alanine residues present in the amyloid 
protein and were capable of binding to the aliphatic amino acids residues at various positions within 
the protein, mainly Aβ12–28 (Figure 6a). More than one molecule was also provided to interact with the 
protein structure as it has been proposed that the molar ratios for successful Aβ fibril and aggregate 
inhibition by Curcumin are greater than a 1:1 ratio [9].  
On  the  other  hand,  the  ability  of  nicotine  to  up-regulate  the  deficient  nicotine  receptors  and 
covalently bind to helical Aβ structures hypothesized it as a neuroprotective agent in AD. Its metabolite 
nornicotine, and more specifically the glycosylated product formed by reaction of nornicotine with the 
ring-opened form of glucose to give the corresponding Amadori product, has been reported to cause 
aberrant nornicotine-based glycation of amyloid protein [12]. This 1,2-dicarbonyl-containing compound 
provides  a  reactive  electrophile  capable  of  covalently  modifying  protein  residues  by  binding  to 
aromatic residues such as phenylalanine and histidine (Figure 6). Therefore, this covalent chemical 
event may also preferentially alter the neurotoxicity of potentially toxic soluble aggregates thereby 
providing  an  intriguing  and  potentially  valuable  treatment  for  AD  and  other  neurodegenerative 
disorders. Importantly, the ANN selected  NEs, Curcumin and Glyconornicotine, were found to be 
interacting more specifically to the fragment VHHQKLVFFAEDVGSNK (Aβ12–28) which has been 
shown to be responsible for peptide aggregation in previous studies [9,12].  Int. J. Mol. Sci. 2011, 12                       
 
 
704 
Figure  6.  Visualization  of  binding  of:  (a)  curcumin-glutamine  acid  [Aβ25];  and 
(b) glycosylated nornicotine- histidine and phenylalanine [Aβ13 & Aβ20] with Aβ protein. 
The NEs and the H-bonded residues (red) are depicted in tube rendering. 
 
2.3.2. Docking Studies 
To  further  analyze  the  molecular  basis  of  interaction  and  affinity  of  binding  of  Curcumin  and 
Glyconornicotine  onto  the  Aβ1-42  peptide,  the  NEs were docked into the active site of  the Aβ1–42 
peptide. Docking results of these NEs are shown in Table 5. The ranking of NEs was based on the 
Glide score. Both NEs accepted poses with the protein (1Z0Q). The difference in Glide score between 
the  NEs  was  minimal  (± 0.9)  which  revealed  that  the  binding  mode  of  both  Curcumin  and 
Glyconornicotine  to  Aβ1-42  may  be  considered  similar.  Results  also  demonstrated  that  docking 
simulations  were  able  to  dock  both  NEs  at  the  fragment  VHHQKLVFFAEDVGSNK  (Aβ12–28) 
(Figure 7), even though they can form H-bonds at different sites as detailed later in this paper. Since 
Curcumin and Glyconornicotine have approximately the same sensitivity towards Aβ as revealed by 
ANN, it is therefore apparent that they may bind in a similar pattern to the active site of Aβ.  
Table 5. Docking results of curcumin and glyconornicotine in the original crystal structure 
of amyloid β protein (1Z0Q) using Glide-xp. 
Rank  Ligand 
No. of poses 
generated 
Glide score  ΔScore 
H-bond
a 
length (A˚) 
Emodel
b 
(kcal/mol) 
1  Curcumin  10  −3.79  −0.9(1–2)  2.73  −37.3 
2 
Glycosylated 
nornicotine 
10  −2.89  +0.9(2–1)  1.89  −33.3 
a Average of all bond lengths 
b Emodel is a specific combination of GScore, CvdW and the internal torsional energy of the ligand 
conformer. Int. J. Mol. Sci. 2011, 12                       
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Upon  comparison  between  the  docking  results  of  Curcumin and  Glyconornicotine, the docking 
score was found to be superior in the case of Curcumin. However, Glynornicotine displayed sufficient 
interaction with the receptor especially in terms of H-bonding (which is considered an important factor 
in protein ligand interaction). In the case of Curcumin, 10 poses were generated, of which only four 
showed H-bonding interaction. On the contrary, in the case of Glyconornicotine, all 10 poses formed 
H-bonds. Figure 7 demonstrates the top-ranked poses with values indicating the H-bonding distances. 
Since all three distances are =/<2 Å this represents rather strong H-bonding interaction. The specific 
residue binding results of docking was consistent with the Molecular Mechanics simulation results as 
Glyconornicotine  exhibited  common  H-bonding  with  phenylalanine  in  both  the  cases.  This 
demonstrated the efficiency and accuracy of applied modeling methodologies in the present work for 
the alignment and generation of poses. 
Figure 7. Binding of Curcumin (C) and Glyconornicotine (G) to respective sequences of 
the Aβ1-42 peptide with H-bond formation of the optimal poses docked into 1Z0Q also 
shown. (a) C: possibility of 2 H-bonds between the proteins (residues highlighted in pink); 
(b) C: highly stable pose apart from optimal conformation and (c) G: optimal pose with 
values (magenta indicates H-bonding distances). 
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2.4. Isobolographic Analysis 
The neuroprotective potential of Curcumin (C) and Glyconornicotine (G) was explored in a unique 
way involving the possibility of their synergistic action in terms of energy minimizations owing to 
different interaction sites as described by the docking studies. The potential of modeling Curcumin and 
Glyconornicotine  in  combination  as  a  highly  minimized  energy  of  Aβ  protein-NE  complex  in  a 
synergistic manner was undertaken. The NEs, curcumin and glycosylated nornicotine, were modeled 
alone  (2,  3  and  4  molecules  in  the  case  of  Curcumin  and  1,  2,  3,  4  and  5  molecules  for 
Glyconornicotine) as well as in combination as fixed ratios of equi-effective energy responses for each 
NE. Several Molecular Mechanics investigations were performed to explore the individual effect of the 
NEs by modeling increasing number of molecules with the protein using AMBER Force Field (Table 
6). The iso-effect (referred to as the minimum total energy achieved) was determined to be the highest 
response with the maximum number of NE molecules in the case of individual NEs versus the number 
of molecules in combination to produce the same effect (Table 6). Therefore, the total minimized 
energy achieved with four Curcumin molecules and five Glyconornicotine molecules was considered to 
be the iso-effect. 
Table 6. Computed energy parameters (kcal/mol) of the protein-NE complexes. 
Molecule 
Total 
Energy
d 
Bond 
Length
e 
Bond 
Angle
f 
Dihedral
g  Vdw
h  H-bond
i  ES
j 
AβP  −642.583  8.816  112.076  54.040  −80.426  −11.192  −728.898 
AβP-(C)1
a  −582.939  11.447  179.994  80.810  −104.533  −17.946  −732.712 
AβP-(C)2  −652.313  9.643  121.259  68.974  −102.424  −18.382  −731.383 
AβP-(C)3  −660.406  11.318  139.298  104.718  −138.832  −18.819  −757.09 
AβP-(C)4  −682.039  12.910  150.151  115.683  −164.561  −17.052  −779.169 
AβP-(C)5  −676.414  13.833  158.07  127.859  −179.578  −17.251  −779.348 
AβP-(G)1
b  −666.074  9.135  119.259  61.920  −104.552  −18.627  −733.21 
AβP-(G)2  −673.763  9.402  122.92  66.095  −120.558  −18.899  −732.723 
AβP-(G)3  −681.320  9.718  123.795  70.168  −137.011  −19.282  −728.71 
AβP-(G)4  −691.403  10.076  129.734  71.880  −151.861  −20.955  −730.279 
AβP-(G)5  −698.344  10.536  132.023  77.219  −169.188  −21.046  −727.889 
AβP-(G)6  NOT Converged (13125 cycles 28811 points) 
AβP-(C)1-(G)1
c  −702.102  9.752  121.608  80.58  −127.923  −17.01  −769.11 
a AβP-(C)n: n is the number of molecule(s) of curcumin. 
b AβP-(G)n: n is the number of molecule(s) of glyconornicotine. 
c AβP-(C)n-(G)n: n is the number of molecule(s) of curcumin and glyconornicotine. 
d Total steric energy for an optimized structure. 
e Bond stretching contributions, reference values were assigned to all of a structure's bond lengths. 
f Bond angle contributions, reference values were assigned to all of a structure's bond angles. 
g Torsional contribution arising from deviations from optimum dihedral angles. 
h van der Waals interactions due to non-bonded interatomic distances. 
i Hydrogen-bond energy function. 
j Electrostatic energy. 
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MM+ simulations were then performed using combinations such as C1-G1, C1-G2, C2-G1 and so 
forth to achieve the iso-effect energy level. Interestingly, the response obtained by AβP-(C)1-(G)1 was 
superior to that of four and five molecules of Curcumin and Glyconornicotine, respectively. Further, 
the  isobologram  of  the  combination  of  Curcumin  and  Glyconornicotine  demonstrated  that  the 
experimentally derived energy values decreased below the theoretical molecule-additive limit, and the 
quantitative parameter (Λ) of the theoretical additive point and those of the experimental point did not 
overlap (Figure 8). This indicated a significant difference between the experimental and the theoretical 
additive point (P < 0.05) and a synergistic interaction between Curcumin and Glyconornicotine in the 
static  lattice  atomistic  simulations.  In  addition,  the  total  fraction  value  was  0.45,  which  was  <1, 
indicating a synergistic interaction (Table 7). 
Figure 8. Isobologram showing the interaction between Curcumin and Glyconornicotine 
on the energetic response of Molecular Mechanics simulations. The number of molecules 
(for  an  energy  minimized  stable  structure)  of  Curcumin  and  Glyconornicotine  are 
contrived. The profile connecting the minimum energy points is the theoretical additive 
line,  and  the  theoretical  additive  point  (▲)  for  the  NE  combination  is  shown  on  the 
additive line. The minimized energy value (■) of the combination of the two NEs was 
significantly lower than the theoretical additive value, indicating a synergistic interaction.  
 
Table 7. Quantitative parameter (Λ) determination for interaction between curcumin and 
glycosylated nornicotine. 
Molecule  Response (units) 
aAβP-(Curcumin)4 
  −682.039 
bAβP-(GlycoNorNicotine)5 
  −698.344 
Isoeffect
*  −690.192 
cAβP-(Curcumin)1-
d(GlycoNorNicotine)1
   −702.102 
Quantitative parameter (Λ)**  0.45 
*Average of AβP-(Curcumin)4 and AβP-(GlycoNorNicotine)5 
0.45
5
1
4
1
b
d
a
c
*Λ *       Int. J. Mol. Sci. 2011, 12                       
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2.5. Design of Experiments 
It is fast becoming standard practice in research and development to employ Design of Experiments 
(DOE) methods, especially in the later stages of development, when the goal shifts from screening to 
product and process optimization [28]. Response Surface Methodology (RSM), such as the Central 
Composite Design,  is the most popular class of RSM designs [29]. In this study a Face-Centered 
Central Composite Design (FCCCD) (Mintab
® V15, Minitab Inc., Boston, MA, USA) was employed 
with two study variables namely the number of Curcumin (C) and Glyconornicotine (G) molecules. 
The number of molecules of curcumin (X1) and glycosylated nornicotine (Glyconornicotine) (X2) was 
selected  as  the  independent  variables  studied  at  two  levels  each  (2–4  for  curcumin  and  1–5  for 
Glyconornicotine). Natural variable level settings for both molecules were used. The design consisted 
of four cube points, five center-points in cube, four axial points (points parallel to each variable axis on 
a circle of radius equal to 1.0 and origin at the center-point) and 0 axial center-points. An α = 1.0 
defined a geometrically square design that was both rotatable and orthogonally blocked. Orthogonally 
blocked designs allow for model terms and block effects to be estimated independently and minimize 
the variation in the regression coefficients [30]. Rotatable designs provide the desirable property of 
constant prediction variance at all points that are equidistant from the design center, thus improving the 
quality of the prediction [31]. Since it was not be possible to have both properties for the FCCCD 
design that was selected, Minitab
® opted for orthogonal blocking and simultaneously attempted to 
converge  as  close  as  possible  to  the  α  value  for  rotatability.  In  order  to  ensure  the  successful 
optimization  and  prediction  from  the  design,  the  region  of  operability  encompassed  the  region  of 
interest.  The  upper  and  lower  limits  of  the  independent  variables  were  determined  by  modeling 
multiple  NEs  simultaneously.  AβP-(C)1  and  AβP-(C)5 were  eliminated  due  to  having  higher  total 
energy values as compared to and AβP and AβP-(C)4, respectively while AβP-(G)6 failed to converge 
even after 13125 cycles (Table 8). The number of Curcumin and Glyconornicotine molecules was in 
the region of interest described by the variable ranges. The design consisted of a two level full factorial 
with a total of 13 experimental runs. 
Based on the orthogonal features of the design, a series of polynomial equations with one variable 
was obtained with the other six variables set at zero. Analysis of Variance (ANOVA), correlation 
analysis,  path  analysis,  and  regression  analysis  was  used  to  analyze  the  dataset  and  statistical 
acceptability of the models proposed. The axial points and replicates were added to the design to 
provide for estimation of curvature of the models and to allow for estimation of experimental error. 
Table 8. Randomized Face-Centered Central Composite Experimental Design Template. 
F#  C
a  G
b  Total 
Energy
c 
Bond 
Length
d 
Bond 
Angle
e 
Dihedral
f  Vdw
g  H-
bond
h 
ES
i 
1  4  1  −727.66  11.79  141.36  104.69  −181.21  −16.98  −787.32 
2  4  3  −741.28  12.79  148.87  112.83  −225.90  −15.13  −774.75 
3  2  3  −737.52  11.13  131.88  96.25  −186.38  −15.23  −775.20 
4  3  3  −733.11  12.06  145.71  111.11  −199.46  −14.81  −787.73 
5  3  5  −723.80  12.49  145.85  115.90  −231.79  −17.25  −748.99 
6  2  5  −718.92  11.83  139.50  109.48  −214.81  −17.74  −747.17 
7  4  5  −716.37  12.63  151.29  116.57  −256.36  −16.10  −724.40 Int. J. Mol. Sci. 2011, 12                       
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Table 8. Cont. 
F#  C
a  G
b  Total 
Energy
c 
Bond 
Length
d 
Bond 
Angle
e 
Dihedral
f  Vdw
g  H-
bond
h 
ES
i 
8  3  3  −710.02  11.92  138.78  101.08  −198.06  −16.54  −747.21 
9  3  1  −720.89  11.01  132.18  87.816  −158.60  −17.95  −775.35 
10  2  1  −717.16  10.29  123.51  86.057  −148.40  −17.22  −771.40 
11  3  3  −732.58  12.05  148.88  112.68  −222.08  −17.40  −766.71 
12  3  3  −743.03  12.76  148.15  108.23  −227.16  −15.31  −769.70 
13  3  3  −728.71  11.84  148.35  113.06  −217.03  −17.36  −767.57 
a Curcumin 
b Glyconornicotine 
c Total steric energy for an optimized structure 
d Bond stretching contributions, reference values were assigned to all of a structure's bond lengths 
e Bond angle contributions, reference values were assigned to all of a structure's bond angles 
f Torsional contribution arising from deviations from optimum dihedral angles 
g van der Waals interactions due to non-bonded interatomic distances 
h Hydrogen-bond energy function 
i Electrostatic energy 
2.5.1. Analysis of the Face-Centered Central Composite Design 
The  correlation  of  the  independent  variables  and  the  responses  were  estimated  by  polynomial 
equations, using the least-square method. From a statistical point of view, three tests were used to 
evaluate  the  adequacy  of  the  models;  Student‘s  t-test  which  is  about  the  significance  of  factors,  
R-square  test  and  Fisher  tests.  It  was  found  that  the  individual  effects  were  significant  at  a  5% 
significance level and only the interactions (CG), (CC), (GG) were not significant and were excluded 
during optimization. The test of reliability was performed by Fisher‘s variance ratio test known as the 
F-test. The tabulated F values at a 5% level of significance were between 1.08 and 12.42. Hence, it was 
concluded that the two variances are equal and that most of the response variation can be explained by 
the  regression.  Furthermore,  the  test  for  significance  of  regression  confirmed  that  the  established 
models provided an excellent fit to the observed data (Figure 9). Finally, the R
2-value was found to be 
significantly high for the Bond Length, Bond Angle and Van der Waals forces with values of 89.9%, 
89.0% and 92.8% respectively (Table 9). These variables were considered statistically relevant for both 
Curcumin  and  Glyconornicotine  and  therefore  considered  further  in  this  study  to  proceed  with 
optimization. In general, results also revealed that the difference between the measured and the fitted 
values  did  not  exceed  3%  indicating  that  the  models  can  adequately  represent  the  data.  At  a 
significance level of 0.05, the mean Curcumin and Glyconornicotine appeared not to be significant to 
the Total Energy (Table 9).  Int. J. Mol. Sci. 2011, 12                       
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Table 9. Pertinent statistical descriptors for determining the model adequacy (p-values and R
2). 
  C
a  G
b  C
2c  G
2d  CG
e  R
2 
Total Energy 
 
0.649  0.796  0.529  0.068  0.537  43.5 
Bond Length 
 
0.001*  0.001*  0.478  0.097  0.287  89.9 
Bond Angle 
 
0.001*  0.003*  0.221  0.091  0.435  89.0 
Dihedral 
 
0.010  0.001*  0.678  0.224  0.283  86.1 
VdW 
 
0.003*  0.000*  0.880  0.106  0.696  92.8 
H-bond 
 
0.414  0.659  0.172  0.027  0.479  57.6 
ES 
 
0.812  0.006*  0.843  0.164  0.154  74.0 
a Curcumin           
b GlycoNorNicotine         
c Curcumin*Curcumin        
d GlycoNorNicotine*GlycoNorNicotine    
e Curcumin*GlycoNorNicotine       
* indicates statistically significant values 
Estimated Regression Coefficients for all molecular attributes  
Total Energy = -731.182 - 1.951C + 1.103G - 4.005C
2 + 13.048G
2 + 3.263CG     (1) 
Bond Length = 12.122 + 0.6593C + 0.6423G - 0.1377C
2 - 0.3519G
2 - 0.1760CG   (2) 
Bond Angle = 145.220 + 7.771C + 6.597G - 2.946C
2 - 4.303G
2 - 1.512CG    (3) 
Dihedral = 108.264 + 7.051C + 10.566G - 1.294C
2 - 3.981G
2 - 2.886CG     (4) 
VdW = -211.158 - 18.980C - 35.792G + 1.011C
2 + 11.950G
2 - 2.182CG      (5) 
H-bond = -16.2168 + 0.3307C + 0.1756G + 0.8547C
2 - 1.5644G
2 + 0.3488CG    (6) 
ES = -769.414 + 1.218C + 18.915G - 1.493C
2 + 11.298G
2 + 9.670CG      (7) 
where, C = curcumin and G = glyconornicotine 
The sequential and adjusted sums of squares (i.e., Seq SS and Adj SS) (Table 3) were identical for 
all terms since the design matrix was orthogonal (Table 10).  
Table 10. Analysis of Variance for all molecular attributes. 
  Total 
Energy 
Bond 
Length 
Bond 
Angle 
Dihedral  VdW  H-bond  ES 
aSeq SS  545.95  5.7884  751.627  1070.68  10361.38  8.3031  2907.70 
bAdj SS   545.95  5.7884  751.627  1070.68  10361.38  8.3031  2907.70 
cP-value  0.447  0.002*  0.003*  0.006*  0.001*  0.212  0.050 
dF  1.08  12.42  11.30  8.69  18.09  1.90  3.98 
a Sequential Sum of Squares (Source: Regression) 
b Adjusted Sum of Squares (Source: Regression) 
c P-value (Source: Regression) 
d F (Source: Regression) Int. J. Mol. Sci. 2011, 12                       
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Figure  9.  Linear  correlation  plots  between  fitted  and  actual  values  for  (a)  total  steric 
energy; (b) bond length contributions; (c) bond angle contributions; (d) dihedral torsional 
contribution;  (e)  Van  der  Waals  interactions;  (f)
  hydrogen-bond  energy  function  and 
(g) electrostatic energy. 
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Figure  10a–c  displays  the  diagnostic  data  for  the  design.  The  residuals  versus  fitted  profiles 
displayed a large randomized spread in the data points for the highest fitted values. However, it is 
difficult to reject the assumption of constant variance in the residuals. The residuals for the variable 
Van de Waals (VdW) that was selected for optimization among the Bond Length and Bond Angle 
followed a relatively bell-shaped curve, though the Normal probability plot had two values off linearity 
at either end (corresponding to high and low values). This further established the significance of VdW 
in  binding  of  Curcumin  and  Glyconornicotine  to  Aβ  to  afford  neuroprotection.  However,  for  the 
variables Bond Length and Bond Angle (Figures 10a,b) the p-value for the Anderson Darling test for 
Normality was >0.05 as well as the histograms displaying a bias in the frequency of the residuals below 
and above baseline. Hence the null hypothesis of Normality cannot be rejected and the mean of the 
residuals was zero. The I-chart (Individuals control chart) in the top right hand corner of Figures 10a–c 
assesses the independence assumption, and does not exhibit any concerning features. The variables 
Bond Length, Bond Angle and VdW for the NE combination were included in the statistical design for 
identifying  the  optimal  NE  combination  and  quantity  of  molecules  required  for  neuroprotection. 
Figure 11a-c displays the 2D contour plots obtained for the three pertinent variables, Bond Length, 
Bond  Angle  and  VdW  employed  for  optimization.  The  optimized  region  (of  3 
Curcumin:3 Glynornicotine) is also highlighted on the respective contour plots. 
Figure 10. Linear correlation plots depicting corresponding residual plots for various variables. 
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Figure 10. Cont. 
 
Figure 11. Corresponding Contour Plots of (a) bond length, (b) bond angle and (c) VdW 
vs. Curcumin and Glyconornicotine. The histograms show the frequency distribution of the 
13 runs with respect to normality from the optimized value.  
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Figure 11. Cont. 
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2.5.2. Response Optimization  
The Response Optimizer tool of Minitab
® V15 (Minitab Inc., Boston, MA, USA) was used to obtain 
the optimized levels of Curcumin and Glyconornicotine based on their molecular attributes in terms of 
Bond  Length,  Bond  Angle  and  VdW.  A  single  optimal  combination  was  obtained  following 
constrained  optimization  of  the  three  variables  as  represented  in  Table  11.  Upon  comprehensive 
evaluation  of  feasibility  searches  and  subsequently  exhaustive  grid  searches,  a  neuroprotective 
combination of three molecules of Curcumin and three molecules of Glyconornicotine fulfilled the 
maximum  requisites  of  an  optimum  combination  primarily  due  to  superior  regulation  of  energy 
attributes. Figure 12 shows the desirability plots of each constraint for the optimized combination. 
Table 12 displays the local solution for Bond Length, Bond Angle and VdW in terms of the desirability 
score, predicted response, the actual response after Molecular Mechanics simulations of the optimized 
combination  along  with  the  percentage  prediction  errors.  The  prediction  error  for  the  response 
parameters ranged between 1.1 and 3.1% with the value of absolute error of 2.36. The low values of 
error indicated the high prognostic ability of the FCCCD employed in this study. 
Table 11. Variable constraints employed for response optimization. 
Parameters  Goal  Lower  Target  Upper  Weight 
Bond Length  Target  10  12  12.5  1 
Bond Angle  Target  123  148  148.5  1 
VdW  Minimum  −256  −256  −1.00  1 
Table 12. Actual and predicted response values for the optimized formulation. 
Local Solution  Desirability  Predicted 
Responses 
Actual 
Responses 
Error (%) 
Bond Length  0.75547  12.1223  12.4932  2.9 
Bond Angle   0.88880  145.2200  149.7621  3.1 
VdW  0.91242  −211.1582  −213.5112  1.1 
Absolute error = 2.36 Int. J. Mol. Sci. 2011, 12                       
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Figure  12.  Desirability  plots  depicting  the  requisite  variables  for  attributes  of  optimal 
combination with the desired targeted responses. 
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2.6. Discussion 
This study provides a foremost comprehensive in silico evidence across combinatorial interventions 
for the potential neuroprotection and neurotherapy of Alzheimer‘s disease (AD). In silico methods 
were  developed  to  establish  predictive  models  for  concentration  dependent  interaction  of 
neuroprotective entities (NEs) for modulating Aβ protein aggregation and oligomerization (Figure 13). 
Firstly, an extensive database search was performed to retrieve a library of small molecules, such as 
apigenin,  congo  red,  curcumin,  dihydroxybenzophenone,  glycosylated  nornicotine, 
hexadecylmethylpiperidinium,  indomethacin,  neocuproine,  polystyrene  sulfonate  and  thioflavin  T, 
reportedly having high affinity for binding with Aβ protein leading to chemical disruption of the Aβ 
folding. Secondly, static lattice atomistic simulations, using ChemBio3D Ultra 11.0 and HyperChem
TM 
8.0.8,  were  performed  throughout  the  study  for  quantifying  the  molecular  attributes  of  the  
protein-ligand(s)  interactions  in  the  terms  of  various  pertinent  energy  attributes  and  to  generate 
preliminary  data  for  protein-ligand  sensitivity  analysis,  ligand-ligand  interaction  studies  and 
combinatorial optimization. Thirdly, selection of NEs based on sensitivity analysis, employing ANN 
using NeuroSolutions
® V5, was conceded and the molecules Curcumin and Glycosylated nornicotine 
demonstrated higher sensitivities toward energy minimizations with Aβ based upon the Mean Square 
Error and input-output mapping.  
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Figure 13. Schematic summarizing the in silico theoretical molecular model developed in 
this study for the screening of neuroprotective entities for Alzheimer‘s disease. 
 
Ligand selection was then followed by a detailed interaction studies using a more focused fragment-
based geometrical optimization. This ‗‗binding surface hypothesis‘‘ was later substantiated through the 
use of docking studies (Glide 4.0). Previous studies have demonstrated the nicotine-based enhancement 
of memory function and reduction of cognitive deficits associated with experimental models of AD 
through multiple mechanisms, such as an increase in the expression of nicotinic acetylcholine (ACh) 
receptors,  stimulating  cortical  ACh  release  and  expression  of  cholinergic  markers  mediated  by 
neurotrophic factors [32]. Additionally, an important mechanism involving the glycation of Aβ protein 
by  glycosylated  nornicotine  recognized  the  chemical  potential  of  this  secondary  metabolite  to 
participate  in  potentially  detrimental  covalent  chemistry  leading  to  pathological  consequences  of 
nornicotine based protein glycation [12]. In our molecular modeling and docking studies, we explored 
the  possible  sites  for  glycation  of  Aβ  within  VHHQKLVFFAEDVGSNK  (Aβ12–28)  residues. 
Interestingly, the glucose side-chain of glycosylated nornicotine exhibited H-bonding with histidine 
and phenylalanine in the case of Molecular Mechanics simulations and with glutamine, phenylalanine 
and aspartic acid during the docking studies. Phenylalanine binding may potentially lead to glycation of 
the VFF tripeptide sequence of the Aβ protein which has been reported to be responsible for Aβ12–28-Int. J. Mol. Sci. 2011, 12                       
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induced amnesia in a mouse model of Aβ toxicity [33]. Our in silico findings in terms of potential 
glycation sites, in addition to lysine reported by Dickerson and Janda (2003) [12], may lead to further 
exploration  of  the  pathological  consequences  of  nornicotine-based  protein  glycation.  On  the  other 
hand, curcumin delivery has  been reported to  have pleiotropic activities relevant  to  AD including 
stimulation of phagocytic Aβ clearance, anti-inflammatory and antioxidant activity, metal chelation, 
neurogenesis and Aβ- and Tau-binding properties [9,34]. In the present study, we modeled the Aβ-
binding properties of Curcumin for the exploration of possible interaction sites. The binding outcome 
varied in both the case as Curcumin exhibited binding with glutamine and glutamic acid in case of 
Molecular  Mechanics  simulations  and  docking  studies  respectively.  Additionally,  Curcumin 
demonstrated binding to the ends of the full Aβ (data not shown). 
Once  the  different  binding  sites  were  confirmed,  a  Curcumin  and  Glyconornicotine  interaction 
analysis was performed for synergism, if any. A highly synergistic interaction was observed displaying 
a possible reduction in individual effective concentration by a factor of 4 and 5, respectively, without 
compromising and even substantiating the therapeutic benefit. This reduction in concentration levels 
may have implications in overcoming the notions related to nicotine-addiction and low brain uptake of 
Curcumin.  Finally,  combinatory  optimization  in  terms  of  requisite  variables  and  maximum-
stabilization  with  the desired targeted responses was  conducted employing  Design of Experiments 
using  Minitab
®  V15.  A  neuroprotective  combination  of  three  molecules  of  Curcumin  and  three 
molecules of Glyconornicotine was proposed by the model indicating a possible 1:1 combination with 
maximum of three molecules of each NE per Aβ oligomer. Thus, our work offers a mathematical and 
in silico approach that constitutes a new frontier in providing neuroscientists with a template for in 
vitro  and  in  vivo  molecular  experimentation.  Future  work  is  recommended  in  terms  of  in  vivo 
pharmacokinetic and pharmacodynamic modeling for the verification of the above theoretical modeling. 
3. Experimental Section 
3.1. Preparation of Protein Target Structure and Compound Libraries 
The starting coordinates of the Alzheimer's disease (AD) amyloid β(1–42) peptide (Aβ1–42) [PBD 
ID: 1Z0Q] and AD amyloid β(1–42) fibrils [PBD ID: 2BEG] were obtained from the Protein Data 
Bank (www.pdb.org) [35] and further modified for molecular mechanics and docking computations. 
The coordinates of ligand Neuroprotective Entities (NEs) (Figure 14) were obtained from the ChEBI 
database  (Chemical  Entities  of  Biological  Interest)  (www.ebi.ac.uk/chebi)  [36]  and  included  the 
following:  apigenin  (ChEBI:  18388),  congo  red  (ChEBI:  34653),  curcumin  (ChEBI:  3962), 
indomethacin (ChEBI: 49662) and polystyrene sulfonate (PSS) [ChEBI: 53280]. Inhibitor derivatives 
such  as  dihydroxybenzophenone  (DHB),  hexadecyl-N-methylpiperidinium  (HMP)  and  glycosylated 
nornicotine  (GlycoNorNicotine)  were  built  using  benzophenone  (ChEBI:  41308),  piperidinium  ion 
[ChEBI:  48633]  and  nornicotine  [ChEBI:  28313]  as  templates,  respectively.  Neocuproine  and 
Thioflavin T (ThT) (PubChem: 16953) were selected from The Timely Data Resources (TDR) Targets 
Database (www.tdrtargets.org) [37] and PubChem (www.pubchem.ncbi.nlm.nih.gov) [38]. Int. J. Mol. Sci. 2011, 12                       
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Figure 14. Neuroprotective Entities (NEs) employed in this study for modeling simulations. 
 
3.2. Static Lattice Atomistic Simulations  
Molecular  Mechanic  Computations  in  vacuum  were  performed  using  HyperChem
TM  8.0.8 
Molecular Modeling Software (Hypercube Inc., Gainesville, FL, USA) and ChemBio3D Ultra 11.0 
(CambridgeSoft Corporation,  Cambridge, UK). The Aβ1–42 peptide molecule and Aβ1–42 fibril was 
downloaded using the GetNetFile Tool in ChemBio3D Ultra in their syndiotactic stereochemistry as 
3D models and saved in an appropriate HyperChem
TM compatible file format for further processing 
and computations. The structure of Aβ12–28 peptide chain was generated using the Sequence Editor 
Module on HyperChem
TM. Structures of various Aβ inhibitor ligand Neuroprotective Entities (NEs) 
were constructed employing innate bond angles as defined in Hyperchem
TM. The models were initially 
energy-minimized  using  MM+  Force  Field  and  the  resulting  structures  were  once  more  
energy-minimized using the AMBER (Assisted Model Building and Energy Refinements) Force Field. 
The conformer having the lowest energy was used to create the target-ligand complexes. A complex of 
one  molecule  with  another  was  assembled  by  parallel  disposition,  and  the  same  procedure  of  
energy-minimization was  repeated to  generate the final  models constituting:  AβP-CR  (congo red), 
AβP-HMP  (hexadecyl-N-methylpiperidinium),  AβP-ThT  (thioflavin  T),  AβP-C  (curcumin),  AβP-G 
(glyconornicotine),  AβP-APG  (apigenin),  AβP-DHB  (dihydroxybenzophenone),  AβP-IND Int. J. Mol. Sci. 2011, 12                       
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(indomethacin), AβP-NEO (neocuproine), AβP-PSS (polystyrene sulfonate) (for selection of the most 
sensitive Aβ-inhibitor/neuroprotective entity using Artificial Neural Networks sensitivity testing) and 
curcumin-AβP-glyconornicotine molecules at varying concentrations (for optimization of the highly 
minimized  ternary  complex  using  a  Face-Centered  Central  Composite  Design).  Full  geometrical 
optimizations  were  performed  in  vacuum  employing  the  Polak–Ribiere  conjugate gradient method 
until a Root Mean Square (RSM) gradient of 0.001 kcal/mol was reached. Force Field options in the 
AMBER (with all hydrogen atoms explicitly included) and MM+ (extended to incorporate non-bonded 
restraints) methods were set at HyperChem
TM user defaults. For Molecular Mechanics computations, 
the Force Fields were utilized with a distance-dependent dielectric constant scaled by a factor of 1. The 
1–4  scale  factors  were  as  follows:  electrostatic  0.5  and  van  der  Waals  0.5.  Furthermore,  various 
energies and molecular attributes involved in the molecular interactions were computed. 
3.3. Sensitivity Testing by Artificial Neural Networks for Optimal Neuroprotective Entity Selection 
Sensitivity testing and optimization was conducted by employing a feedback Multilayer Perceptron 
(MLP)  neural  network  to  train  the  empirical  input  bond-energy  data  with  static  back  propagation 
(NeuroSolutions
® V5, FL, USA). The MLP is a layered feedforward network typically trained with 
back propagation of errors using gradient descent or conjugate gradient algorithms. The advantage of 
being able to approximate any input/output map makes an MLP highly useful in applications requiring 
static pattern classification [39]. Figure 15 illustrates the typical MLP network constructed and the 
network topology for the hidden input and output layers. A genetic algorithm with a Sigmoid Axon 
transfer  function  and  Conjugated  Gradient  learning  rule  was  employed  for  the  hidden  input  and 
output layers.  
Figure 15. Schematics depicting the constructed Multilayer Perceptron network and the 
network  topology  for  the  hidden  input  and  output  layers  employing  Artificial 
Neural Networks. 
 
3.4. Prediction of the Structure and Binding Affinity of Target-Ligand Complexes 
For preparation of the protein target structure, the Aβ complex obtained from the Protein Data Bank 
was modified for docking computations via Glide 4.0 software (Schrö dinger LLC, New York, NY, 
USA,  2005).  The  computations  were  performed  by  importing  the  Aβ  complex  to  Maestro 
(Schrö dinger) along with identifying and eliminating co-crystallized ligands and further minimized 
using  the  Protein  Preparation  wizard  applying  an  OPLS-AA  Force  Field  (autoref.pl  script). 
Minimizations  were  performed  until  the  average  Root  Mean  Square  (RSM)  deviation  of  the 
non-hydrogen atoms  reached 0.3  Å [40]. The ligand (obtained from databases as described in the Int. J. Mol. Sci. 2011, 12                       
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materials section) analogue library was generated by modifying the respective functional groups using 
the reagent database and a combinatorial design module. Each structure was assigned an appropriate 
bond order (LigPrep script). The inhibitors were converted to Mae format (Maestro, Schrodinger, Inc.) 
and optimized by means of the MMFF94 Force Field using user defaults [41]. Glide 4.0 computations 
such as docking and scoring functions were performed with various scaling factors for the Van der 
Waal  radii  of  the  receptor  and  ligand  atom.  The  receptor-grid  files  were  generated  using  a  Grid-
Receptor Generation algorithm after ensuring that the protein and ligands were in the correct form for 
docking. The size of ligands to be docked was selected from the workspace and was docked with the 
active site using the ‗Xtra Precision‘ algorithm. Conformations were generated internally and conceded 
these through a series of filters involving Grid-Based Force Field evaluation and refinement of docking 
solutions including torsional and rigid body motions of the ligand using the OPLS-AA Force Field. 
The surviving docking solutions were then subjected to Monte Carlo procedure minimization of energy 
scores and the final energy evaluations were performed with GlideScore to generate the single best 
pose as the output for a particular ligand. 
3.5. Interaction Studies Employing Isobolographic Analysis 
The Loewe additivity relationship was used to analyze interactions between each Neuroprotective 
Entity (NE). The equation assumes that the fractional effect contributed from each NE is additive to 
explicate  the  entire  response  from  combinations.  The  Combination  Index  (Λ)  is  calculated  using 
Equation (8). 
* n C
n C
...
* 2 C
2 C
* i C
1 C
Λ                         (8) 
where, Ci are the concentrations of various NEs in combination, and C1* are the concentrations of 
various NEs that would produce the same effect when used alone. A ―Λ‖ of <, =, or > 1 indicates 
synergy, additivity, and antagonism, respectively [42]. Isobolographic analysis for the combination of 
most sensitive NEs (as determined by ANN), in terms of contribution to the energy minimization of 
target-ligand  complex,  was  conducted  based  on  comparisons  of  a  number  of  interacting  ligand 
molecules  that  were  determined  to  be  equi-effective.  The  NEs  were  modeled  alone  as  well  as  in 
combination as fixed ratios of equi-effective energy responses for each NE. The energy minimized 
confirmations of the combined NEs were used to compute the various pertinent energies and molecular 
attributes involved in the molecular interactions. The isobolos were constructed by plotting the Total 
Energy values of one NE on the independent axis and that of other as the dependent variable, modeled 
alone and in combination. 
3.6. Design of Experiments 
A Face-Centered Central Composite Design (FCCCD) with α = 1 was employed as per standard 
protocol. The number of molecules of NEs, X1 and X2, were selected as the independent variables 
studied at two levels each (2–4 for curcumin and 1–5 for glyconornicotine). The upper and lower limits 
were determined by performing MM+ simulations of protein-NE complexes as shown in Table 6. The 
central point (0, 0) was studied in quintuplicate. All other processing variables were kept invariant Int. J. Mol. Sci. 2011, 12                       
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throughout the study. Table 8 summarizes an account of the 13 experimental runs studied, their factor 
combinations and the responses obtained after subsequent modeling simulations undertaken. The Total 
Energy, Bond Length, Bond Angle, Dihedral, Van der Waals, H-Bonding and Electrostatic energies 
were specified as the response variables. Various Response Surface Methodology computations for the 
current optimization study were performed employing Minitab
® V15 software (Minitab Inc., Boston, 
MA,  USA).  Polynomial  models  including  interaction  and  quadratic  terms  were  generated  for  the 
response variables using Multiple Linear Regression Analysis (MLRA). The general form of the model 
is represented in Equation (9). 
Y = β0 + β1X1 + β2 X2 + β3 X1 X2 + β4 X1
2 + β5 X2
2 + β6 X1 X2
2 + β7 X1
2 X2               (9) 
where, β0 is the intercept representing the arithmetic average of all quantitative outcomes of 13 runs; β1 
to β7 are the coefficients computed from the observed experimental values of Y; and X1 and X2 are the 
coded  levels  of  the  independent  variable(s).  The  terms  X1X2  and  Xi
2  (i  =  1  to  2)  represent  the 
interaction and quadratic terms, respectively. Statistical validity of the polynomials was established on 
the  basis  of  ANOVA  provision  in  the  Minitab
®  V15  software.  Subsequently,  feasibility  and  grid 
searches  were  performed  to  locate  the  composition  of  the  optimum  combinations  (i.e.,  optimum 
number of NE molecules to ensure Aβ binding and neuroprotection). In addition, 2D contour plots 
were constructed using the design outputs generated in order to visualize the data regions of interest. 
Numerical optimization using the desirability approach was employed to locate the optimal settings of 
the  independent  variables  in  order  to  obtain  the  desired  response.  An  optimized  formulation  was 
developed  by  setting  constraints  on  the  dependent  and  independent  variables.  The  optimized 
combination developed was evaluated for the responses and the experimental values obtained were 
compared with those predicted by the mathematical models generated. 
4. Conclusions 
Our approach was to assay a library of potential neuroprotective entities (NEs) that were previously 
reported to address binding features that are critical for inhibition of Aβ aggregation. Our findings 
indicate that a combination of NEs may result in synergistic activity with a significant reduction in 
dose. Firstly, in the ANN sensitivity testing, we selected curcumin and glyconornicotine as the most 
sensitive NEs toward stabilizing the Aβ protein. It is worth noting that, both these compounds have 
been  shown  to  inhibit  Aβ  aggregation  by  other  experimental  approaches  [9,12].  In  the  second 
component of our study, we used isobolographic analysis simultaneously with Design of Experiments 
to deduce the interrelation between both the NEs in terms of synergism and their collective influence 
on the Aβ binding at concentration rations of ligand:ligand, 1:1, and protein:ligand, 1:3. In addition, the 
molecular basis of interaction and affinity of binding of curcumin and glyconornicotine onto the Aβ1–42 
peptide  was  deduced  using  Molecular  Mechanics  and  Advanced  Docking  computations.  Results 
obtained from in silico from this study suggest that curcumin and glycosylated nornicotine can form a 
potential  neuroprotective  and  neurotherapeutic  combination  against  aggregated  Aβ  that  causes 
Alzheimer‘s disease. We anticipate that in future neuroscientists would adopt this in silico approach to 
develop  novel  therapeutic  interventions  for  the  neuroprotection  and  neurotherapy  of  Alzheimer‘s Int. J. Mol. Sci. 2011, 12                       
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disease  or  as  a  template  for  other  therapeutic  strategies.  In  addition,  the  neuroprotective  entities 
identified in this study may also be valuable in this regard. 
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